Novartis AG
NVSDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 16, 2026 | $4.74 | 2026-03-11 | 2026-03-11 |
| April 25, 2025 | $3.99 | 2025-03-12 | 2025-03-12 |
| April 19, 2024 | $3.74 | 2024-03-07 | 2024-03-08 |
| March 20, 2023 | $3.50 | 2023-03-09 | 2023-03-10 |
| March 17, 2022 | $3.33 | 2022-03-08 | 2022-03-09 |
Dividends Summary
- Consistent Payer: Novartis AG has rewarded shareholders with 23 dividend payments over the past 22 years.
- Total Returned Value: Investors who held NVS shares during this period received a total of $58.49 per share in dividend income.
- Latest Payout: The most recent dividend of $4.74/share was paid 124 days ago, on March 16, 2026.
- Yield & Schedule: NVS currently pays dividends yearly with an annual yield of 3.08%.
- Dividend Growth: Since 2004, the dividend payout has grown by 506.8%, from $0.78 to $4.74.
- Growth Streak: NVS has raised its dividend for 8 consecutive payments.
Company News
Novartis announced FDA traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgAN. The drug demonstrated a 48% reduction in eGFR decline versus placebo over two years in the Phase III APPLAUSE-IgAN study. Fabhalta is the first complement inhibitor approved for this indication and represents a signifi...
The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% ...
Novartis and Teva represent different pharmaceutical strategies: Novartis is a stable innovator with high margins and strong cash flow, while Teva is executing a turnaround from generics to biosimilars with improving profitability but higher debt. Despite Novartis's superior financial metrics, the article recommends Teva for long-term investors d...
The Vanguard International Dividend Appreciation ETF (VIGI) offers exposure to 343 global stocks from developed markets with a low 0.07% expense ratio, but has delivered underwhelming returns and a modest 2.13% dividend yield. The fund is heavily concentrated in Japan (30.9%) and Canada (23%), and has been significantly outperformed by the S&P 50...
Vanguard Health Care ETF (VHT) offers broad diversification across 429 healthcare holdings with a low 0.09% expense ratio, while VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to 26 drugmakers with higher returns but greater risk. VHT is more cost-effective and diversified, while PPH has delivered superior 5-year returns and highe...
